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TO THE EDITOR:
We duly note the insurance challenges discussed by 
authors Eswaran and Chan. Many insurance payers 
continue to require fixed pretransplant sobriety peri-
ods (ie, the 6-month rule) despite the lack of evidence 
to support them.(1-3) Although payers reserve the right 
to have skepticism about any center’s evolving poli-
cies regarding liver transplantation (LT) for alcoholic 
associated hepatitis (AH), we anticipate that payers’ 
approach to these patients will progress. As transplant 
centers update their institutional criteria regarding 
LT for AH, acceptable outcomes are demonstrated 
in a transparent manner, and professional societies 
offer guidance, we anticipate that insurance payers’ 
policies will follow suit.(4) Notably, to achieve success 
this should include coverage for LT and for essential 
mental health and substance-use disorder (MH/SUD) 
treatment before and after LT.
Drinking is one of innumerable behaviors, habits, and 
choices that affect human health and medical outcomes. 
Other key transplant examples include patient adher-
ence to medications and clinic visits as well as weight and 
nutrition management. In an era of alarming alcohol- 
related trends,(5) the transplant field must simultane-
ously work diligently to maintain stigma-free, equita-
ble, high standards for organ allocation while striving 
to provide excellent MH/SUD care for recurrent alco-
hol-use disorder (AUD) in LT patients regardless of 
indication.
Other meaningful actions by transplant centers may 
also help. We agree with the importance and efficacy of 
integrative medicine, embedded MH/SUD care, and 
longitudinal case management within transplant as 
highlighted by authors Solga and Spacek. Expansion of 
pretransplant and posttransplant psychosocial person-
nel and services that are highly cross-trained in MH/
SUD and transplant whenever possible, demonstrates 
a center’s commitment to high level relapse monitoring 
and its expanded ability to intervene.(6) Centers must 
facilitate MH/SUD care plans consistently over the 
years after transplant given variable trajectories of post-
transplant drinking.(7) Longitudinal use of toxicology 
(especially biomarkers like serum phosphatidylethanol 
and urinary ethyl glucuronide) and psychometrics are 
helpful tools for monitoring patients undergoing LT 
for AH and for anticipating crises. Given the dense 
populations and broad geographic areas transplant cen-
ters serve, established collaborations with community 
MH/SUD providers as well as the use of telemedicine 
may ease insurance payers’ concerns about LT patient 
follow-up and care access. Centers should track and 
publish a wider array of outcomes with LT for AH. 
In addition to “harder” survival, graft failure, and slip/
relapse outcomes, meaningful “softer” LT outcomes, 
such as AUD treatment retention, successful AUD 
treatment re-engagement, regained sobriety, men-
tal health and quality of life metrics, and postrelapse 
renormalization of liver function tests, will be essential 
for measuring effective care with LT for AH. Payers 
may also be reassured to see that, in an age of clini-
cian burnout, transplant centers prioritize the mental 
health of their own staff given the challenges inherent 
to managing MH/SUD matters in LT patients.
Although LT in AH patients is a vital issue of the day, 
human behavior, habit, and addiction remain, on the 
whole, intrinsic to all aspects of LT.
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